These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8075793)

  • 1. Pathogenicity determinants of Candida albicans: potential targets for immunotherapy?
    Matthews RC
    Microbiology (Reading); 1994 Jul; 140 ( Pt 7)():1505-11. PubMed ID: 8075793
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of Anti-Virulence Approaches for Candidiasis via a Novel Series of Small-Molecule Inhibitors of
    Romo JA; Pierce CG; Chaturvedi AK; Lazzell AL; McHardy SF; Saville SP; Lopez-Ribot JL
    mBio; 2017 Dec; 8(6):. PubMed ID: 29208749
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting Candida albicans filamentation for antifungal drug development.
    Vila T; Romo JA; Pierce CG; McHardy SF; Saville SP; Lopez-Ribot JL
    Virulence; 2017 Feb; 8(2):150-158. PubMed ID: 27268130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candida albicans molecular biology reaches its maturity.
    Larriba G; Rubio Coque JJ; Ciudad A; Andaluz E
    Int Microbiol; 2000 Dec; 3(4):247-52. PubMed ID: 11334309
    [No Abstract]   [Full Text] [Related]  

  • 5. Candida albicans, the opportunist. A cellular and molecular perspective.
    Dupont PF
    J Am Podiatr Med Assoc; 1995 Feb; 85(2):104-15. PubMed ID: 7877106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candida albicans - Biology, molecular characterization, pathogenicity, and advances in diagnosis and control - An update.
    Dadar M; Tiwari R; Karthik K; Chakraborty S; Shahali Y; Dhama K
    Microb Pathog; 2018 Apr; 117():128-138. PubMed ID: 29454824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased resistance in BALB/c mice to reinfection with Candida albicans is due to immunoneutralization of a virulence-associated immunomodulatory protein.
    Tavares D; Ferreira P; Arala-Chaves M
    Microbiology (Reading); 2003 Feb; 149(Pt 2):333-339. PubMed ID: 12624195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Targets for Antifungal Drug Discovery Based on Growth and Virulence in Candida albicans.
    Li X; Hou Y; Yue L; Liu S; Du J; Sun S
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5885-91. PubMed ID: 26195510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic patterns of Candida albicans germ tube antibody in critically ill patients: influence on mortality.
    Zaragoza R; Pemán J; Quindós G; Iruretagoyena JR; Cuétara MS; Ramírez P; Gómez MD; Camarena JJ; Viudes A; Pontón J;
    Clin Vaccine Immunol; 2009 Oct; 16(10):1527-8. PubMed ID: 19675223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Item no 87: cutaneous-mucous bacterial and fungal infections: Candida albicans].
    Ann Dermatol Venereol; 2005 Oct; 132(10 Suppl):7S44-7S49. PubMed ID: 16419520
    [No Abstract]   [Full Text] [Related]  

  • 11. Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans.
    Cui J; Ren B; Tong Y; Dai H; Zhang L
    Virulence; 2015; 6(4):362-71. PubMed ID: 26048362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal Compounds against
    Liu X; Ma Z; Zhang J; Yang L
    Biomed Res Int; 2017; 2017():4614183. PubMed ID: 29445739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of Aspartic Proteases in Candida Virulence. Protease Inhibitors against Candida Infections.
    Monika S; Małgorzata B; Zbigniew O
    Curr Protein Pept Sci; 2017; 18(10):1050-1062. PubMed ID: 27514853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of Upc2p-Inducible
    Luna-Tapia A; Willems HME; Parker JE; Tournu H; Barker KS; Nishimoto AT; Rogers PD; Kelly SL; Peters BM; Palmer GE
    mBio; 2018 May; 9(3):. PubMed ID: 29789366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenic and protective Candida albicans constituents.
    Cassone A; De Bernardis F; Ausiello CM; Gomez MJ; Boccanera M; La Valle R; Torosantucci A
    Res Immunol; 1998; 149(4-5):289-99; discussion 504. PubMed ID: 9720947
    [No Abstract]   [Full Text] [Related]  

  • 16. Candida and allergy.
    Palma-Carlos AG; Palma-Carlos ML; Costa AC
    Allerg Immunol (Paris); 2002 Nov; 34(9):322-4. PubMed ID: 12512190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of anti-Candida antibodies in immunoprophylaxis.
    Cabezas J; Albaina O; Montañez D; Sevilla MJ; Moragues MD; Pontón J
    Immunotherapy; 2010 Mar; 2(2):171-83. PubMed ID: 20635926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs.
    Pierce CG; Lopez-Ribot JL
    Expert Opin Drug Discov; 2013 Sep; 8(9):1117-26. PubMed ID: 23738751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in systemic candidosis.
    Winner HI
    Contrib Microbiol Immunol; 1977; 4():64-76. PubMed ID: 342193
    [No Abstract]   [Full Text] [Related]  

  • 20. Candida and candidiasis: the cell wall as a potential molecular target for antifungal therapy.
    Gozalbo D; Roig P; Villamón E; Gil ML
    Curr Drug Targets Infect Disord; 2004 Jun; 4(2):117-35. PubMed ID: 15180460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.